Skip to main content

Table 3 The relationship between preoperative peripheral blood SII and clinical data in GBC patients

From: Detecting the preoperative peripheral blood systemic immune-inflammation index (SII) as a tool for early diagnosis and prognosis of gallbladder cancer

Clinical pathological factors

Cases

Low SII group

(n = 46)

High SII group

(n = 40)

P value

Age (years) [n (%)]

    

≤ 60

37

21 (45.65%)

16 (40.00%)

0.665

> 60

49

25 (54.35%)

24 (60.00%)

Sex [n (%)]

    

Male

33

17 (36.96%)

16 (40.00%)

0.826

Female

53

29 (63.04%)

24 (60.00%)

BMI [n (%)]

    

≥ 23 kg/m2

30

13 (28.26%)

17 (42.50%)

0.182

< 23 kg/m2

56

33 (71.74%)

23 (57.50%)

Cancer type

    

Adenocarcinoma

52

30 (65.22%)

22 (55.00%)

0.507

Mixed adenocarcinoma

15

8 (17.39%)

7 (17.50%)

Adenosquamous carcinoma

19

8 (17.39%)

11 (27.50%)

Tumor size [n (%)]

    

≤ 5 cm

30

24 (52.17%)

6 (15.00%)

< 0.001

> 5 cm

56

22 (47.83%)

34 (85.00%)

Differentiation degree [n (%)]

    

Low differentiation

26

19 (41.30%)

7 (15.70%)

0.020

Medium/high differentiation

60

27 (58.70%)

33 (82.50%)

TNM staging [n (%)]

    

I-II stage

33

24 (52.17%)

9 (22.50%)

0.007

III-IV stage

53

22 (47.83%)

31 (77.50%)

Lymph node metastasis

    

Yes

39

13 (28.26%)

26 (65.00%)

0.001

No

47

33 (71.74%)

14 (35.00%)

Perineural invasion

    

Yes

30

10 (21.74%)

20 (50.00%)

0.007

No

56

36 (78.26%)

20 (50.00%)

Surgery type

    

Simple cholecystectomy

25

17 (36.96%)

8 (20.00%)

0.001

Radical cholecystectomy

23

18 (39.13%)

5 (12.50%)

Enlarged radical cholecystectomy

21

5 (10.87%)

16 (40.00%)

Palliative surgery

17

6 (13.04%)

11 (27.50%)

Postoperative neoadjuvant chemotherapy

    

Yes

30

14 (30.43%)

16 (40.00%)

0.374

No

56

32 (69.57%)

24 (60.00%)

Chemotherapy regimen

    

Cisplatin + Gemcitabine

 

8 (17.39%)

6 (15.00%)

0.282

Cisplatin + Tegafur

 

6 (13.04%)

10 (25.00%)

NLR

 

1.95(0.63, 8.28)

3.12 (2.08, 5.97)

< 0.001

PLR

 

144.60 ± 26.16

181.91 ± 21.23

< 0.001

CEA (ng/mL)

 

5.80 ± 1.30

6.94 ± 1.58

< 0.001

CA125 (U/mL)

 

47.53 (28.54, 77.11)

71.54 (31.84, 92.39)

< 0.001

CA19-9 (U/mL)

 

110.35 (72.39, 163.45)

148.81 (82.45, 185.30)

< 0.001

  1. Note: BMI: body mass index; TNM: T: extent of the primary tumor; N: lymph node involvement; M: metastatic disease; NLR (neutrophil-to-lymphocyte ratio); PLR (platelet-to-lymphocyte ratio); CEA: carcinoembryonic antigen; CA125: carbohydrate antigen 125; CA19-9: carbohydrate antigen 19 − 9. Fisher’s exact test was for the comparative analysis of categorical variable, and unpaired t-test was for the comparative analysis of continuous variables between two groups. Measurement data with non-normal distribution were expressed as median (minimum, maximum). Mann-Whitney U test was used for comparisons between groups. P < 0.05 indicated a statistically significant difference
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us